AdvanCell raises $218.3 million in Rule 506(b) equity offering
AdvanCell, a Delaware biotechnology corporation, has sold $218,333,294 of a $315,000,000 equity offering under Regulation D Rule 506(b), as of June 30, 2026.
$218M$315Mequity
Company
SEC filing news and material events for AdvanCell, Inc., briefed from primary-source filings.
1 story
AdvanCell, a Delaware biotechnology corporation, has sold $218,333,294 of a $315,000,000 equity offering under Regulation D Rule 506(b), as of June 30, 2026.